Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Cancer Immunol Immunother ; 56(10): 1667-76, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17440724

ABSTRACT

Application of tetrameric MHC class I-peptide complexes has significantly improved the monitoring of antigen-specific T cell immune responses in mouse models as well as in clinical studies. Especially MHC class I tetramer analysis of tumor-specific T cells in suspension or on thick vibratome sections from viable tissue has been proven extremely useful. Using the well-characterized mouse tyrosinase-related-protein-2 specific cytotoxic T cell (CTL) clone LP9, we now developed a method that allows for specific identification of T cells with MHC class I tetramers in 8 mum thick, chemically fixed cryosections. The protocol was validated in a murine influenza virus-infection model. Moreover, analysis of delayed type hypersensitivity (DTH) skin biopsies from melanoma patients vaccinated with peptide-loaded mature dendritic cells, revealed the presence and location of anti-tumor CTLs. The specificity of the CTLs detected in situ correlated with both the DTH challenge specificity and reactivity of cell suspensions derived from the same biopsies. Collectively, our data demonstrate that in situ MHC class I tetramer staining provides a valuable tool to reveal the presence and anatomical location of specific CTLs in frozen tissue following immune-based treatment strategies in cancer patients.


Subject(s)
Antigens, Neoplasm/analysis , Dendritic Cells/transplantation , Histocompatibility Antigens Class I/analysis , Melanoma/therapy , Skin Neoplasms/therapy , T-Lymphocytes, Cytotoxic/immunology , Animals , CD8 Antigens/analysis , Cryoultramicrotomy , Dendritic Cells/immunology , Disease Models, Animal , Humans , Hypersensitivity, Delayed/immunology , Hypersensitivity, Delayed/pathology , Influenza, Human/immunology , Melanoma/immunology , Mice , Skin Neoplasms/immunology , Staining and Labeling , Vaccination
3.
Br J Cancer ; 83(10): 1351-9, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11044361

ABSTRACT

To investigate whether the course of primary melanoma disease correlates with expression of the various components of the proteolytic plasminogen activation (PA) system, immunohistochemical stainings for activators of plasminogen (tissue type (tPA) and urokinase type (uPA)), inhibitors of plasminogen activation (type 1 (PAI-1) and type 2 (PAI-2)) and the receptor for uPA (uPAR) were performed on 214 routinely processed melanoma lesions. All lesions were primary cutaneous melanomas, minimally 1.5 mm thick, and derived from patients with only local disease at the moment of diagnosis (clinically stage II (T(3-4)N(0)M(0)), American Joint Committee on Cancer). Median patient follow-up was 6.1 years. Single variables as immunohistochemical staining results (extent of tumour cell staining, pattern of tumour cell staining and for some components also staining of stromal cells), histopathological and clinical parameters as well as treatment variables were analysed in order to assess their prognostic importance, in terms of time to recurrence, time to distant metastasis and duration of survival. The extent of tPA tumour cell positivity, categorized as 0-5%, 6-50% and 51-100%, appeared to be of importance for these end-points. Lesions with 51-100% tPA-positive tumour cells were found to have the best prognosis, whereas lesions with 6-50% tPA-positive tumour cells had the worst. Moreover, the prognostic significance of Breslow thickness, microscopic ulceration and sex was confirmed in this study. Multivariate analyses, incorporating these relevant factors, showed that the extent of tPA tumour cell positivity was an independent prognostic factor for distant metastasis-free interval (P = 0.012) and for the duration of survival (P = 0.043).


Subject(s)
Melanoma/pathology , Skin Neoplasms/pathology , Tissue Plasminogen Activator/analysis , Urokinase-Type Plasminogen Activator/analysis , Adolescent , Adult , Aged , Disease-Free Survival , Extremities , Female , Follow-Up Studies , Humans , Immunohistochemistry , Male , Melanoma/chemistry , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Predictive Value of Tests , Prognosis , Sensitivity and Specificity , Skin Neoplasms/chemistry
4.
Br J Cancer ; 79(9-10): 1534-41, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10188903

ABSTRACT

Enzyme-linked immunosorbent assay (ELISA) methods and immunohistochemistry (IHC) are techniques that provide information on protein expression in tissue samples. Both methods have been used to investigate the impact of the plasminogen activation (PA) system in cancer. In the present paper we first compared the expression levels of uPA, tPA, PAI-1 and uPAR in a compound group consisting of 33 cancer lesions of various origin (breast, lung, colon, cervix and melanoma) as quantitated by ELISA and semi-quantitated by IHC. Secondly, the same kind of comparison was performed on a group of 23 melanoma lesions and a group of 28 breast carcinoma lesions. The two techniques were applied to adjacent parts of the same frozen tissue sample, enabling the comparison of results obtained on material of almost identical composition. Spearman correlation coefficients between IHC results and ELISA results for uPA, tPA, PAI-1 and uPAR varied between 0.41 and 0.78, and were higher for the compound group and the breast cancer group than for the melanoma group. Although a higher IHC score category was always associated with an increased median ELISA value, there was an overlap of ELISA values from different scoring classes. Hence, for the individual tumour cases the relation between ELISA and IHC is ambiguous. This indicates that the two techniques are not directly interchangeable and that their value for clinical purposes may be different.


Subject(s)
Enzyme-Linked Immunosorbent Assay/methods , Immunohistochemistry/methods , Neoplasms/chemistry , Plasminogen Activator Inhibitor 1/analysis , Receptors, Cell Surface/analysis , Tissue Plasminogen Activator/analysis , Urokinase-Type Plasminogen Activator/analysis , Humans , Receptors, Urokinase Plasminogen Activator
5.
J Histochem Cytochem ; 46(4): 469-76, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9524192

ABSTRACT

We present a systematic analysis of the sensitivity and specificity of immunohistochemical stainings for components of the plasminogen activation system, i.e., uPA, tPA, PAI-1, PAI-2, and uPAR, on routinely processed (formalin-fixed, paraffin-embedded) tissues. Five to nine antibodies per component were tested and the influence of different antigen retrieval regimens on immunoreactivity was investigated. We studied six different microwave-mediated pretreatments and two pretreatments by proteolytic digestion. First, positive and negative control tissues were stained. Then, frozen and paraffin sections from the same cancer lesions were stained after specific modes of pretreatment and with selected antibodies. For each component, one or a few of the tested Abs gave optimal staining on paraffin sections when combined with a particular tissue pretreatment. For PAI-1, and to a lesser degree also for tPA, an underrepresentation of stromal cell staining in paraffin material was found, whereas tumor cells showed good staining. For uPA, PAI-2, and uPAR, consistent staining results were obtained on paraffin sections.


Subject(s)
Epitopes/chemistry , Immunohistochemistry/methods , Neoplasms/metabolism , Plasminogen Activators/metabolism , Plasminogen Inactivators/metabolism , Animals , Epitopes/drug effects , Formaldehyde , Humans , Mice , Paraffin Embedding , Plasminogen Activator Inhibitor 1/metabolism , Plasminogen Activator Inhibitor 2/metabolism , Rats , Tissue Fixation , Tissue Plasminogen Activator/metabolism , Tumor Cells, Cultured , Urokinase-Type Plasminogen Activator/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...